Molecular design and downstream processing of turoctocog alfa (NovoEight), a B-domain truncated factor VIII molecule
Turoctocog alfa (NovoEight) is a third-generation recombinant factor VIII (rFVIII) with a truncated B-domain that is manufactured in Chinese hamster ovary cells. No human or animal-derived materials are used in the process. The aim of this study is to describe the molecular design and purification p...
Main Authors: | Ahmadian, Haleh, Hansen, Ernst B., Faber, Johan H., Sejergaard, Lars, Karlsson, Johan, Bolt, Gert, Hansen, Jens J., Thim, Lars |
---|---|
Format: | Online |
Language: | English |
Published: |
Lippincott Williams And Wilkins
2016
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4935534/ |
Similar Items
-
Turoctocog alfa (NovoEight®) – from design to clinical proof of concept
by: Ezban, Mirella, et al.
Published: (2014) -
Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trials
by: Santagostino, E, et al.
Published: (2015) -
Turoctocog alfa: an evidence-based review of its potential in the treatment of hemophilia A
by: Takedani, Hideyuki, et al.
Published: (2015) -
Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa
by: Santagostino, E, et al.
Published: (2014) -
Full transcriptome analysis of Chinese Hamster Ovary cell lines producing a dynamic range of Coagulation Factor VIII
by: Kaas, Christian S, et al.
Published: (2013)